文献速递泌尿生殖与妇科肿瘤放疗

局限性前列腺癌外照射放疗中FLAME局灶增量方案个体化的风险建模

Risk Modeling for Individualization of the FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With Localized Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-09-18

基于FLAME试验(NCT01168479)526例患者,分析临床特征与D98%分布,用惩罚Cox回归建立预测模型,比较标准全腺77 Gy与局灶增量D98% 95 Gy的5年DFS预测;结果显示GG 1患者在77 Gy下DFS已较高,而高风险特征(尤其GG 4或5)患者5年DFS低,局灶增量可能大幅改善。

要点

  • GG 1患者在标准剂量77 Gy下预测DFS已较高,局灶增量的额外获益有限。
  • 高风险特征患者(尤其GG 4或5)在77 Gy下5年DFS低,局灶增量可能大幅改善。
  • 接受D98% > 85 Gy的120例患者中高风险因素代表良好且复发较少。

核心结论

  • 结果提示GG 1患者在标准剂量77 Gy下失败率已较低,限制了局灶增量的额外获益。
  • 高风险特征患者尤其GG 4或5的5年DFS低,而局灶增量可能大幅改善,提示达到高局灶增量剂量可能对这些患者特别有益。

研究设计与样本

  • 基于FLAME试验(NCT01168479)526例患者的分析,描述临床特征及高风险因素数量与D98%的分布。
  • 采用惩罚Cox回归开发预测模型,比较假设标准全腺放疗77 Gy与额外局灶增量D98% 95 Gy的5年DFS预测。

主要发现

  • 接受D98% > 85 Gy的120例患者中高风险因素代表良好,且与接受77 Gy组相比复发较少。
  • 应用模拟标准剂量77 Gy的模型,预测GG 1患者DFS高,而高风险特征患者DFS低。
  • 模拟D98% 95 Gy时所有风险组均显示高DFS水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The FLAME trial (NCT01168479) showed that isotoxic focal boosting to the intraprostatic lesion(s) in patients with intermediate- and high-risk prostate cancer improves 5-year disease-free survival (DFS). Although the near-minimum dose to the gross tumor volume (D98%) was associated with improved outcomes, a closer look suggested that this might not be the same for all patients. Therefore, we investigated whether risk factors that are associated with a benefit of focal boosting can be identified. METHODS AND MATERIALS: We described the distribution of clinical characteristics and the number of high-risk factors with respect to the D98% in 526 FLAME trial patients. We used penalized Cox regression to develop a prediction model. To investigate a potential benefit in patient subgroups, we compared the model-based predictions of 5-year DFS assuming standard whole-gland radiation therapy of 77 Gy to the predictions assuming an additional focal boost with D98% of 95 Gy. RESULTS: Patients with high-risk factors were well represented in the group of 120 patients that received D98% > 85 Gy and showed fewer recurrences compared with the group that received 77 Gy. Applying the model simulating a standard dose of 77 Gy, we predicted a high DFS for grade group (GG) 1 patients, whereas patients with high-risk characteristics appeared to show a low DFS. All risk groups showed a high level of DFS when simulating D98% of 95 Gy. CONCLUSIONS: Our results suggest that GG 1 patients already show a low level of failure at a standard dose of 77 Gy, limiting the additional benefit of focal boosting. In contrast, patients with high-risk characteristics, especially GG 4 or 5, show a low 5-year DFS, while focal boosting might improve this substantially. This suggests that reaching a high focal boost dose may be particularly beneficial for these patients.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Menne Guricová K, Groen V, Pos F, et al. Risk Modeling for Individualization of the FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2023. PMID: 37725026. doi:10.1016/j.ijrobp.2023.07.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。